Tempus AI, Inc. has agreed to acquire genomics company Personalis, Inc. in an all-stock transaction valuing the cancer-testing firm at roughly $1.5 billion, deepening its push to build an end-to-end, AI-driven precision oncology platform. The definitive agreement, announced on July 20, 2026, offers Personalis shareholders $16.25 per share, with Tempus holding an option to pay up to 50% of the consideration in cash.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...
Contact us
Questions, corrections, or ideas? Send us a message here. We aim to reply by email within 24 hours.
Thank you. Your message has been sent. We aim to reply by email within 24 hours.Please enter your email address and a message.We could not send your message. Please try again in a little while.